| Similar Articles |
|---|
 |
BusinessWeek
October 10, 2005
Catherine Arnst |
Is This Disease For Real? Metabolic syndrome may put you at higher risk for heart disease and diabetes, but many doctors question the diagnosis.   |
Nursing
September 2010
Margaret M. Bolton |
Sounding the alarm about metabolic syndrome Any health problem that affects a third of American adults is sure to impact your nursing practice. Metabolic syndrome, a growing and commonly silent condition, poses a significant public health crisis. |
Nutrition Action Healthletter
October 2001 |
Read My Lipids How to lower your risk of a heart attack... |
BusinessWeek
September 1, 2009
Catherine Arnst |
Opportunities in the Obesity Epidemic Drugmakers are ratcheting up research into treatments for gout and other ills that plague the overweight. |
American Family Physician
June 15, 2004
Darwin Deen |
Metabolic Syndrome: Time for Action Family physicians can be more effective in helping patients to change their lifestyle behaviors by assessing each patient for the presence of specific risk factors, clearly communicating these risk factors to patients, identifying appropriate interventions to address specific risks, and assisting patients in identifying barriers to behavior change. |
Managed Care
December 2004
Jack McCain |
The Weight Debate, Continued This article presents the views of people who indulge in what many regard as health care heresy. They challenge the conventional wisdom that millions of Americans need to lose tons of weight, fast, to stave off diabetes, heart disease, cancer. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Orexigen Drug Shows Potential as "Two-Fer" Against Obesity and Diabetes Orexigen's latest drug aims at treating both diabetes and obesity. |
BusinessWeek
December 27, 2004
Kerry Capell |
The End Of Obesity As We Know It Sanofi-Aventis' Acomplia takes aim at two of the great maladies of the century. But approval isn't a slam dunk. |
The Motley Fool
July 14, 2010
Luke Timmerman |
Vivus Faces Turning Point Tomorrow Thursday's the big day. All eyes will be on Vivus and the FDA's decision on their new obesity drug |
The Motley Fool
June 3, 2011
Luke Timmerman |
Orexigen, Facing High Hurdle at FDA, Puts Obesity Drug Development on Hold The close attention paid to safety makes this drug difficult to get right. |
BusinessWeek
December 22, 2003
Arlene Weintraub |
Big Pharma Looks Beyond Insulin Researchers may be on the verge of major new treatments for diabetes and obesity. |
Chemistry World
December 2006
Dennis Rouvray |
Fat of the Land As we become progressively more rotund, our body chemistry undergoes critical changes that have a major impact on our health. |
The Motley Fool
July 16, 2010
Tom Hughes |
Lessons Learned About the Outlook for New Obesity Drug Approval The recent FDA advisory committee meeting on Vivus' weight loss pill proved to us, once again, how incredibly difficult it is to successfully develop and register new drugs for obesity. |
The Motley Fool
February 8, 2011
Esterhuizen & Sellitti |
Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch. |
Pharmaceutical Executive
October 1, 2006
Rob Scott |
Thoughtleader: Life After Lipitor A conversation with a former Pfizer executive who "launched the world's best-selling drug." |
Nursing Management
January 2012
Lawrence et al. |
Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support. |
American Family Physician
April 15, 2004
Rao, Disraeli & Mcgregor |
Impaired Glucose Tolerance and Impaired Fasting Glucose Impaired glucose tolerance and impaired fasting glucose form an intermediate stage in the natural history of diabetes mellitus. |
American Family Physician
June 1, 2001
James M. Lyznicki |
Obesity: Assessment and Management in Primary Care Obesity is a complex, multifactorial condition in which excess body fat may put a person at health risk. National data indicate that the prevalence of obesity in the United States is increasing in children and adults... |
American Family Physician
December 15, 2000
Alan J. Garber |
Attenuating Cardiovascular Risk Factors in Patients with Type 2 Diabetes All cardiovascular risk factors except smoking are more prevalent in patients with type 2 diabetes. In addition to exercise, weight control, aspirin therapy and blood pressure control, therapy to modify lipid profiles is usually necessary... |
Managed Care
January 2006
Martin Sipkoff |
Skeptics Abound as Demand Grows For Obesity Treatments Changes in reimbursement patterns for obesity drugs will take several years. Lifestyle changes remain the first approach. |
The Motley Fool
March 2, 2011
Susmita Chatterjee |
How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others? |
BusinessWeek
May 8, 2006
Catherine Arnst |
Hey, You Don't Look So Good As diagnoses of once-rare illnesses soar, doctors say drugmakers are "disease-mongering" to boost sales. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
The Motley Fool
December 14, 2005
Stephen D. Simpson |
Arena Fattens Wallets Positive phase 2 data sends the biotech's stock up big and raises hopes of a blockbuster. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
American Family Physician
March 1, 2002
Richard S. Safeer |
Cholesterol Treatment Guidelines Update In addition to modifying current strategies of risk assessment, the new guidelines stress the importance of an aggressive therapeutic approach in the management of hypercholesterolemia... |
The Motley Fool
September 2, 2010
Luke Timmerman |
Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb San Diego-based Orexigen Therapeutics has found a partner to help it compete in the growing market for drugs to combat obesity, Japan-based Takeda Pharmaceutical. |
The Motley Fool
December 23, 2010
Brian Orelli |
Corcept May Have Hit Pay Dirt Corcept's Corlux tackles Cushing's syndrome. |
American Family Physician
March 15, 2001
Goutham Rao |
Insulin Resistance Syndrome Insulin resistance can be linked to diabetes, hypertension, dyslipidemia, cardiovascular disease and other abnormalities. Because resistance usually develops long before these diseases appear, identifying and treating insulin-resistant patients has potentially great preventive value... |
Searcher
June 2012
Stephanie C. Ardito |
The Medical Digital: How Safe Are the Prescription Drugs we Take? Monitoring Adverse Events and Recalls For general information about prescription and clinical trial drugs, the following websites have been around for a while and have excellent reputations. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
July 13, 2010
Brian Orelli |
A Triple Delight: 3 Stocks All Up More Than 10% What's good for the obese goose is good for the gander when it comes to new drug treatments for losing weight. |
Nursing Management
March 2012
Yvonne D'Arcy |
Pain and obesity It can be a challenge to provide effective pain management for obese patients; however, a multimodal pain management regimen that combines medications and complementary techniques can help increase pain relief. |
BusinessWeek
September 3, 2009 |
Beyond Diabetes: Diseases Related to Obesity Four diseases linked to obesity. |
AskMen.com
Dave Golokhov |
Short Workouts Shorter, more intense training is better for your health than longer, leisurely workouts |
The Motley Fool
June 29, 2010
Brian Orelli |
Diabetes Drug Development Pops and Drops When companies present at a major meeting, there's bound to be both. |
Nurse Practitioner
December 2011 |
Managing pain in obese patients Obesity-related pain conditions can limit the patient's efforts at increasing activity and limit quality of life. This article will offer information on these conditions and treatment options. |
The Motley Fool
June 25, 2010
Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
The Motley Fool
April 5, 2005
Stephen D. Simpson |
Can Obesity Fatten Your Wallet? Obesity is an increasingly serious problem, but could it also be a major opportunity for health-care companies? Investors should spend a little due diligence on the pharmaceutical side. |
Nurse Practitioner
September 2011
Cheryl L. Gainer |
Celiac Disease: Helping Patients Live Gluten-Free A review of the screening, diagnosis, and treatment of celiac disease. |
Chemistry World
July 18, 2012
Andrew Turley |
Obesity drug approved in US US regulators have approved a new obesity treatment. Qsymia (phentermine, topiramate) tablets have been approved for overweight adults as part of a regimen that includes a low calorie diet and exercise. |
Managed Care
March 2000
Michael D. Dalzell |
Where Society Failed, Can Health Plans Succeed? What can be done about obesity? By engaging patients and forming strategic alliances, plans can gain immediate cost and clinical benefits -- despite conventional wisdom to the contrary. |
American Family Physician
July 15, 2000
Ethan M. Berke & Nancy E. Morden |
Medical Management of Obesity Family physicians must treat any conditions associated with obesity while working with patients on methods to achieve and maintain weight loss... |
American Family Physician
October 15, 2003
Gavin et al. |
Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes By increasing patient awareness of the link between diabetes and heart disease, family physicians can encourage patients to take medications (including aspirin), stop smoking, lower blood pressure, and lower cholesterol and blood glucose levels. |
Nursing
August 2008
Carl A. Kirton |
Managing Long-Term Complications of HIV Infection Now that advances in treatment have transformed HIV into a chronic, manageable disease, patients are facing cardiovascular and metabolic complications you might not have expected 15 years ago. Here's how to help your patient manage them. |
The Motley Fool
November 23, 2009
Brian Orelli |
The Side Effect of Developing Obesity Drugs The FDA is fickle when it comes to weight-loss drugs. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
September 23, 2010
Brian Orelli |
Ugly Side Effects Won't Derail This Drug Side effects don't matter much when there are no other treatment options, as in Cushing's disease. |
The Motley Fool
June 3, 2011
Brian Orelli |
FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully. |
American Family Physician
March 15, 2003
McInnis et al. |
Counseling for Physical Activity in Overweight and Obese Patients An estimated 97 million adults in the United States, or more than six out of 10 men and women, are overweight or obese. The role of physicians and other health care professionals is associated with greater efforts to help patients adopt healthy lifestyle habits related to diet and exercise. |
